氨甲环酸对中度至重度贫血产妇产后出血的影响(WOMAN-2):一项国际、随机、双盲、安慰剂对照试验
WOMAN-2 试验在四个国家 34 家医院纳入血红蛋白 <100 g/L 的经阴道分娩产妇,随机接受产后 15 分钟内静脉注射氨甲环酸 1 g 或安慰剂。氨甲环酸组临床诊断产后出血 7.0%,安慰剂组 6.6%(RR 1.05,95%CI 0.94-1.19),未降低产后出血风险;两组均无血管闭塞事件及治疗相关不良事件。
要点
- 中度至重度贫血产妇产后 15 分钟内静脉氨甲环酸 1 g 未降低临床诊断产后出血风险(RR 1.05,95%CI 0.94-1.19)。
- 氨甲环酸组产后出血 7.0%(530/7579),安慰剂组 6.6%(497/7487)。
- 两组均未报告血管闭塞事件(肺栓塞、深静脉血栓、卒中、心肌梗死)及治疗相关不良事件或死亡。
核心结论
- 在中度至重度贫血产妇中,脐带钳夹后 15 分钟内给予氨甲环酸未能降低临床诊断产后出血的风险。
研究设计与样本
- 国际、随机、双盲、安慰剂对照试验,在尼日利亚、巴基斯坦、坦桑尼亚和赞比亚四国 34 家医院进行。
- 招募任何年龄、活跃产程中、血红蛋白 <100 g/L 的中度或重度贫血产妇,经阴道分娩后按 1:1 随机分配。
- 干预为脐带剪断或钳夹后 15 分钟内缓慢静脉注射(超过 10 分钟)氨甲环酸 1 g 或匹配安慰剂。
- 主要结局为随机化后 24 小时内临床诊断的原发性产后出血,按意向性治疗分析;安全性分析纳入所有意向性治疗人群。
- 2019 年 8 月 24 日至 2023 年 9 月 19 日期间,邀请 16 586 名 14-50 岁女性参与,排除 1518 名,7580 名分配至氨甲环酸组、7488 名分配至安慰剂组。
主要发现
- 氨甲环酸组临床诊断产后出血 530/7579(7.0%),安慰剂组 497/7487(6.6%),RR 1.05(95%CI 0.94-1.19)。
- 从开始给予试验治疗到诊断产后出血的中位时间间隔为 18.5 分钟(IQR 5-58);中度贫血为 20 分钟(IQR 8-64),重度贫血为 13 分钟(IQR 7-44)。
- 在 1024 例有产后出血时间数据的产妇中,358 例(35%)在试验治疗完全给药前即被诊断。
- 预设亚组分析(贫血严重程度 p=0.44、产前出血 p=0.044、产道创伤 p=0.37、疼痛控制使用 p=0.37、产后出血基线风险 p=0.31)均无强烈证据反对效应同质性。
- 两组均未报告血管闭塞事件(肺栓塞、深静脉血栓、卒中、心肌梗死),无治疗相关不良事件及治疗相关死亡。
关键数值与推荐
- 主要结局:氨甲环酸组 530/7579(7.0%)vs 安慰剂组 497/7487(6.6%),RR 1.05(95%CI 0.94-1.19)。
- 贫血严重程度亚组分析 p=0.44;产前出血亚组 p=0.044;产道创伤亚组 p=0.37;疼痛控制使用亚组 p=0.37;产后出血基线风险亚组 p=0.31。
- 从开始给药到诊断产后出血的中位时间:总体 18.5 分钟(IQR 5-58);中度贫血 20 分钟(IQR 8-64);重度贫血 13 分钟(IQR 7-44)。
- 1024 例有产后出血时间数据的产妇中,358 例(35%)在试验治疗完全给药前被诊断。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tranexamic acid, given within 3 h of birth, reduces bleeding deaths in women with postpartum haemorrhage. We examined whether giving tranexamic acid shortly after birth can prevent postpartum haemorrhage in women with moderate or severe anaemia. METHODS: This international, randomised, double-blind, placebo-controlled trial was done in 34 hospitals across four countries (Nigeria, Pakistan, Tanzania, and Zambia). We recruited women of any age in active labour with moderate or severe anaemia (haemoglobin <100 g/L). We randomly assigned women (1:1) who had given birth vaginally to receive 1 g of tranexamic acid or matching placebo by slow intravenous injection (over 10 min) within 15 min of the umbilical cord being cut or clamped. Women were randomly assigned by selection of the lowest numbered treatment pack from a box containing 20 packs that were identical apart from the pack number. Participants, care givers, and those assessing outcomes were masked to group assignment. The primary outcome was a clinical diagnosis of primary postpartum haemorrhage, which might be an estimated blood loss of more than 500 mL or any blood loss sufficient to compromise haemodynamic stability within 24 h of randomisation, analysed on an intention-to-treat basis. Safety analyses were performed in all participants included in the intention-to-treat population. This trial was registered on ISRCTN (ISRCTN62396133), ClinicalTrials.gov (NCT03475342), and the Pan African Clinical Trial Registry (PACTR201909735842379) and is closed to recruitment. FINDINGS: From Aug 24, 2019, to Sept 19, 2023, 16 586 women aged 14-50 years were invited to take part and 1518 were excluded. 7580 women were randomly assigned to receive tranexamic acid and 7488 to receive placebo. Primary outcome data were unavailable for one woman in each group. The median time interval from the start of the administration of the trial treatment to the diagnosis of postpartum haemorrhage was 18·5 min (IQR 5-58); 20 min (8-64) in women with moderate anaemia and 13 min (7-44) in women with severe anaemia. 358 (35%) of 1024 with postpartum haemorrhage for whom time data were available were diagnosed before the trial treatment had been fully administered. Clinically diagnosed postpartum haemorrhage occurred in 530 (7·0%) of 7579 in the tranexamic acid group and in 497 (6·6%) of 7487 in the placebo group (risk ratio [RR] 1·05, 95% CI 0·94-1·19). There was no strong evidence against the null hypothesis of homogeneity of effects for any of the prespecified subgroup analyses: severity of anaemia (p=0·44), antepartum haemorrhage (p=0·044), birth canal trauma (p=0·37), use of pain control (p=0·37), and baseline risk of postpartum haemorrhage (p=0·31). There were no vascular occlusive events (pulmonary embolism, deep vein thrombosis, stroke, and myocardial infarction) reported in either group. There were no adverse events related to the treatment and no treatment-related deaths. INTERPRETATION: In women with moderate and severe anaemia, giving tranexamic acid within 15 min of the umbilical cord being clamped did not reduce the risk of clinically diagnosed postpartum haemorrhage. FUNDING: The Bill & Melinda Gates Foundation and the Wellcome Trust.
引用
- The effect of tranexamic acid on postpartum bleeding in women with moderate and severe anaemia (WOMAN-2): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2024. PMID: 39461792. doi:10.1016/S0140-6736(24)01749-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。